查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1927687

全球真實世界證據腫瘤市場：按組件、資料來源類型、治療領域、應用、最終用戶、國家和地區分類－產業分析、市場規模、佔有率和預測（2025-2032）

RWE Oncology Market, By Component, By Data Source Type, By Therapeutic Area, By Application, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 380 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計到 2024 年，RWE 腫瘤市場規模將達到 7.901 億美元，並從 2025 年到 2032 年以 14.90% 的複合年成長率成長。

腫瘤學領域的真實世界證據 (RWE) 指的是收集和分析來自真實世界環境（例如電子健康記錄、患者登記和保險理賠數據）的健康數據，以補充臨床試驗結果。這些證據支持治療效果檢驗、安全性監測和個人化癌症治療決策。市場成長的驅動力來自癌症發生率的上升和基於價值的醫療保健模式的廣泛應用。根據美國國家癌症研究所 (NCI) 預測，2024 年美國將新增約 190 萬例癌症病例，這進一步增加了對真實世界數據的需求，以改善治療效果。隨著數據分析技術的進步、人工智慧的整合以及監管機構的認可，RWE 的應用正在加速癌症藥物的研發，並最佳化全球患者管理。

真實世界證據腫瘤市場動態

更多採用真實世界數據來改善癌症治療效果

全球癌症負擔日益加重，對個人化、實證腫瘤治療的需求不斷成長，推動了對真實世界證據（RWE）解決方案的需求。世界衛生組織（WHO）指出，癌症仍是全球首要死因，預計到2024年將有約1,000萬人死於癌症。這種情況促使人們更加重視利用電子健康記錄、癌症登記處和理賠資料庫的真實世界數據，以補充臨床試驗，提高治療效果和安全性監測。美國食品藥物管理局（FDA）等監管機構正擴大採用RWE來支持藥物核准和適應症擴展，加速市場應用。人工智慧和機器學習的進步使得人們能夠從複雜的腫瘤數據中獲得更深入的洞察，並推動精準醫療的發展。此外，支付者和醫療服務提供者正在強調以價值為基礎的醫療模式，利用RWE來最佳化治療通訊協定並降低成本。對醫療資訊IT基礎設施的投資不斷增加，尤其是在已開發經濟體和新興經濟體，進一步推動了全球成長機會。

真實世界腫瘤市場：細分分析

全球 RWE 腫瘤市場按組件、資料來源類型、治療領域、應用、最終用戶和地區進行細分。

從組成元件來看，該平台由資料來源、分析軟體和服務所構成。資料來源包括電子健康記錄(EHR)、癌症登記資料、理賠和報銷資料、病患報告結果以及基因組資料庫，提供對腫瘤學研究至關重要的多樣化真實世界資訊。分析軟體利用人工智慧和機器學習演算法分析複雜的腫瘤學資料集，以評估治療效果、安全性和預測預後。服務包括諮詢、數據管理和整合，旨在幫助醫療保健相關人員高效實施真實世界證據 (RWE) 解決方案。根據美國國家衛生資訊科技協調辦公室 (ONC) 預測，到 2024 年，醫院中經認證的 EHR 技術採用率將超過 85%，從而為 RWE 提供資料支援。

應用領域涵蓋藥物研發和臨床試驗、治療方案最佳化、監管和支付方決策支持，以及市場進入和醫保報銷。在藥物研發方面，真實世界證據（RWE）可與臨床試驗相輔相成，加速核准並擴大適應症。在治療方案最佳化方面，患者數據可用於個人化治療，進而改善治療效果。在監管和支付方決策支援方面，真實世界資料可用於安全性監測和醫療保險報銷決策。在市場進入和健保報銷方面，RWE 透過展現治療方案的價值和成本效益而獲益，在與支付方談判和納入健保目錄方面發揮著至關重要的作用。

真實世界證據腫瘤市場—區域分析

全球真實世界證據（RWE）腫瘤市場呈現顯著的區域差異，這主要受醫療基礎設施、數據可用性和法規結構的影響。北美市場主導，美國國家癌症研究所（NCI）預測，2024年美國新增癌症病例將超過190萬例，這將推動對真實世界數據的需求，以改善治療效果。美國食品藥物管理局（FDA）的真實世界證據計畫進一步加速了該地區對真實世界數據的應用。歐洲緊隨其後，歐洲癌症資訊系統報告稱，每年新增癌症病例約400萬例，這為各大腫瘤中心開展真實世界數據（RWE）計畫提供了支持。亞太地區預計將實現最快成長，中國國家腫瘤中心預計2023年新增癌症病例將達到480萬例，將推動對醫療數據基礎設施和數位化腫瘤解決方案的投資。在拉丁美洲和中東等新興地區，癌症發病率的上升以及政府為加強醫療數據收集所採取的舉措，正在創造新的市場機會。

美國腫瘤真實世界證據市場—國家分析

美國在全球真實世界證據（RWE）腫瘤市場中處於領先地位，這得益於其先進的醫療保健生態系統、廣泛的腫瘤研究以及對真實世界數據整合的強力的監管支持。根據美國國家癌症研究所（NCI）預測，到2024年，美國將新增約190萬例癌症病例，因此迫切需要透過真實世界證據來加強治療評估。美國食品藥物管理局（FDA）的真實世界證據計畫正在促進更快的核准流程和更完善的上市後監測，從而推動市場成長。 Flatiron Health、IQVIA和Tempus Labs等主要企業正致力於利用龐大的臨床數據、人工智慧分析以及與頂尖癌症中心的合作。美國擁有強大的醫療保健IT基礎設施，預計2023年醫療保健支出將超過4.3兆美元（CMS數據），並且精準癌症治療領域不斷創新，因此，美國已成為全球腫瘤真實世界證據應用的中心。

目錄

第1章 腫瘤真實世界證據市場概述

  • 分析範圍
  • 市場估算期

第2章執行摘要

  • 市場區隔
  • 競爭考察

第3章 真實世界證據腫瘤學的關鍵市場趨勢

  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 未來市場趨勢

第4章 真實世界證據腫瘤市場：產業分析

  • PEST分析
  • 波特五力分析
  • 市場成長展望：概覽
  • 管理體制分析

第5章 真實世界腫瘤市場：地緣政治緊張局勢加劇的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章 真實世界證據腫瘤市場概況

  • RWE腫瘤市佔率分析（2024年）
  • 主要製造商的細分數據
    • 對現有公司的分析
    • 新興企業分析

7. 腫瘤學真實世界證據市場（按組成部分分類）

  • 概述
    • 細分市場佔有率分析：按組成部分
    • 資料集
      • EMR/HER
      • 宣稱
      • 藥局
      • 癌症登記處
    • 整合資料集
    • 諮詢服務

8. 依資料來源類型分類的 RWE 腫瘤市場

  • 概述
    • 細分市場佔有率分析：依資料來源類型分類
    • 臨床數據
    • 計費數據
    • 腫瘤登記處
    • 藥房數據

9. 按治療領域分類的RWE腫瘤市場

  • 概述
    • 細分市場佔有率分析：依治療領域分類
    • 乳癌
    • 肺癌
    • 攝護腺癌
    • 骨髓惡性腫瘤
    • 其他

第10章 按應用分類的RWE腫瘤市場

  • 概述
    • 細分市場佔有率分析：按應用
    • 藥物研發與核准
    • 市場進入和報銷
    • 上市後監測
    • 醫療設備認證
    • 其他

第11章：按最終用戶分類的RWE腫瘤市場

  • 概述
    • 細分市場佔有率分析：依最終用戶分類
    • 製藥、生技和醫療設備公司
    • 醫療保健提供者
    • 醫療保險公司
    • 其他

第12章：按地區分類的RWE腫瘤市場

  • 介紹
  • 北美洲
    • 概述
    • 北美主要製造商
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲主要製造商
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 其他
  • 亞太地區
    • 概述
    • 亞太地區主要製造商
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 其他
  • 拉丁美洲
    • 概述
    • 拉丁美洲主要製造商
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 其他
  • 中東和非洲
    • 概述
    • 中東和非洲的主要製造商
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 其他

第13章 主要供應商分析：真實世界證據腫瘤產業

  • 競爭對手儀錶板
    • 競爭基準
    • 競爭定位
  • 公司簡介
    • IQVIA
    • ICON plc
    • Syneos Health
    • Parexel International
    • Covance（Labcorp）
    • PPD, Inc.
    • PRA Health Sciences（now part of ICON）
    • Charles River Laboratories
    • Medidata Solutions（Dassault Systemes）
    • Clarivate
    • Flatiron Health（owned by Roche）
    • Cerner Corporation（now part of Oracle）
    • Cota Healthcare
    • Evidera（PAREXEL）
    • RealEndeavors
    • Truven Health Analytics（IBM Watson Health）
    • Informa Pharma Intelligence
    • McKesson Corporation
    • Symphony Health（ICON）
    • Others

第14章 AnalystView 360度分析

簡介目錄
Product Code: ANV5973

RWE oncology market size was valued at US$ 790.10 Million in 2024, expanding at a CAGR of 14.90% from 2025 to 2032.

Real-World Evidence (RWE) in oncology involves the collection and analysis of health data from real-world settings such as electronic health records, patient registries, and insurance claims-to complement clinical trial findings. This evidence supports treatment effectiveness, safety monitoring, and personalized cancer care decisions. The market growth is driven by increasing cancer prevalence and the rising adoption of value-based healthcare models. According to the National Cancer Institute (NCI), an estimated 1.9 million new cancer cases were diagnosed in the U.S. in 2024, intensifying the need for real-world data to improve therapeutic outcomes. Advances in data analytics, AI integration, and regulatory acceptance are fostering RWE applications to accelerate oncology drug development and optimize patient management globally.

RWE Oncology Market- Market Dynamics

Growing adoption of real-world data to enhance oncology treatment outcomes

The rising global cancer burden and the need for personalized, evidence-based oncology care are driving demand for RWE solutions. According to the World Health Organization (WHO), cancer remains a leading cause of death globally, accounting for nearly 10 million deaths in 2024. This has intensified the focus on utilizing real-world data from electronic health records, cancer registries, and claims databases to complement clinical trials, improving treatment effectiveness and safety monitoring. Regulatory agencies like the U.S. FDA increasingly accept RWE to support drug approvals and label expansions, accelerating market adoption. Advances in AI and machine learning facilitate deeper insights from complex oncology data, enabling precision medicine. Furthermore, healthcare payers and providers emphasize value-based care models, leveraging RWE to optimize treatment protocols and reduce costs. Growing investments in health IT infrastructure, particularly in developed and emerging economies, further propel market growth opportunities worldwide.

RWE Oncology Market- Segmentation Analysis:

The Global RWE Oncology Market is segmented on the basis of Component, Data Source Type, Therapeutic Area, Application, End User, and Region.

Based on Component, the market includes Data Sources, Analytics Software, and Services. Data Sources encompass electronic health records (EHRs), cancer registries, claims and billing data, patient-reported outcomes, and genomic databases, providing diverse real-world insights critical for oncology research. Analytics Software leverages AI and machine learning algorithms to analyze complex oncology datasets for treatment effectiveness, safety, and outcome prediction. Services include consulting, data management, and integration, which help healthcare stakeholders implement RWE solutions efficiently. According to the U.S. Office of the National Coordinator for Health Information Technology (ONC), adoption of certified EHR technology reached over 85% among hospitals in 2024, supporting data availability for RWE.

Based on Application, the market covers Drug Development & Clinical Trials, Treatment Optimization, Regulatory & Payer Decision Support, and Market Access & Reimbursement. Drug Development utilizes RWE to complement clinical trials, enabling accelerated approvals and label expansions. Treatment Optimization involves personalizing therapy based on patient data to improve outcomes. Regulatory & Payer Decision Support uses real-world insights for safety monitoring and coverage decisions. Market Access and Reimbursement benefit from RWE by demonstrating treatment value and cost-effectiveness, critical for payer negotiations and formulary inclusion.

RWE Oncology Market- Geographical Insights

The global RWE oncology market shows significant regional variation shaped by healthcare infrastructure, data availability, and regulatory frameworks. North America leads with over 1.9 million new cancer cases projected in the U.S. in 2024, according to the National Cancer Institute (NCI), fueling demand for real-world data to improve treatment outcomes. The FDA's Real-World Evidence Program further accelerates adoption in this region. Europe follows, with the European Cancer Information System reporting nearly 4 million new cancer cases annually, supporting RWE initiatives across major oncology hubs. Asia-Pacific is expected to experience the fastest growth, with China's National Cancer Center estimating 4.8 million new cancer diagnoses in 2023, driving investments in healthcare data infrastructure and digital oncology solutions. Emerging regions such as Latin America and the Middle East benefit from increasing cancer incidence and government efforts to enhance healthcare data collection, presenting new market opportunities.

U.S. RWE Oncology Market- Country Insights

The United States leads the global RWE oncology market, propelled by its advanced healthcare ecosystem, extensive oncology research, and strong regulatory support for real-world data integration. According to the National Cancer Institute (NCI), approximately 1.9 million new cancer cases are expected in the U.S. in 2024, driving urgent demand for enhanced treatment evaluation through real-world evidence. The FDA's Real-World Evidence Program facilitates faster approvals and improved post-market surveillance, strengthening the market's growth. Key players such as Flatiron Health, IQVIA, and Tempus Labs focus on leveraging vast clinical data, AI analytics, and partnerships with leading cancer centers. The U.S.'s robust health IT infrastructure, high healthcare spending exceeding $4.3 trillion in 2023 (CMS), and ongoing innovation in precision oncology make it the focal point for real-world evidence applications in oncology worldwide.

RWE Oncology Market- Competitive Landscape:

The rising emphasis on data-driven oncology treatment and real-world evidence utilization is intensifying competition among key market players. Major companies such as IQVIA, ICON plc, Syneos Health, Parexel, Covance, and Flatiron Health lead by leveraging advanced data analytics platforms, AI integration, and comprehensive oncology data registries. Common strategies include strategic acquisitions to enhance data capabilities, partnerships with pharmaceutical companies for tailored oncology solutions, and expanding global footprints to access diverse patient populations. Investment in cloud-based data management and real-time evidence generation tools is prevalent, enabling faster drug development and regulatory approvals. Additionally, companies are focusing on compliance with evolving data privacy regulations and offering customized solutions to meet oncology research demands, strengthening their competitive positions worldwide.

Recent Developments:

In May 2025, Datavant completed its acquisition of RWE specialist Aetion, combining data connectivity and advanced real world evidence analytics into a unified platform. The expanded ecosystem-spanning over 300 data partners across EHRs, claims, registries, and more-aims to help life sciences and healthcare organizations generate faster, scalable, and actionable evidence across the drug development lifecycle.

In April 2025, Atropos Health partnered with Ontada to integrate Ontada's community oncology real world data into the Atropos Evidence(TM) Network, enhancing RWE use cases for clinicians, researchers, and healthcare leaders. This collaboration aims to improve cancer care protocols, advance precision medicine, and accelerate development of new oncology treatments using high quality real world evidence.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL RWE ONCOLOGY MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • IQVIA
  • ICON plc
  • Syneos Health
  • Parexel International
  • Covance (Labcorp)
  • PPD, Inc.
  • PRA Health Sciences (now part of ICON)
  • Charles River Laboratories
  • Medidata Solutions (Dassault Systemes)
  • Clarivate
  • Flatiron Health (owned by Roche)
  • Cerner Corporation (now part of Oracle)
  • Cota Healthcare
  • Evidera (PAREXEL)
  • RealEndeavors
  • Truven Health Analytics (IBM Watson Health)
  • Informa Pharma Intelligence
  • McKesson Corporation
  • Symphony Health (ICON)
  • Others

GLOBAL RWE ONCOLOGY MARKET, BY COMPONENT- MARKET ANALYSIS, 2019 - 2032

  • Datasets
  • EMR/HER
  • Claims
  • Pharmacy
  • Cancer Registries
  • Integrated Datasets
  • Consulting Services

GLOBAL RWE ONCOLOGY MARKET, BY DATA SOURCE TYPE- MARKET ANALYSIS, 2019 - 2032

  • Clinical Data
  • Claims Data
  • Oncology Registries
  • Pharmacy Data

GLOBAL RWE ONCOLOGY MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032

  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Hematologic Malignancies
  • Others

GLOBAL RWE ONCOLOGY MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Drug Development & Approvals
  • Market Access & Reimbursement
  • Post-Market Surveillance
  • Medical Device Approvals
  • Others

GLOBAL RWE ONCOLOGY MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Pharmaceutical, Biotechnology & Medical Device Companies
  • Healthcare Providers
  • Healthcare Payers
  • Others

GLOBAL RWE ONCOLOGY MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. RWE Oncology Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. RWE Oncology Market Snippet by Component
    • 2.1.2. RWE Oncology Market Snippet by Data Source Type
    • 2.1.3. RWE Oncology Market Snippet by Therapeutic Area
    • 2.1.4. RWE Oncology Market Snippet by Application
    • 2.1.5. RWE Oncology Market Snippet by End User
    • 2.1.6. RWE Oncology Market Snippet by Country
    • 2.1.7. RWE Oncology Market Snippet by Region
  • 2.2. Competitive Insights

3. RWE Oncology Key Market Trends

  • 3.1. RWE Oncology Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. RWE Oncology Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. RWE Oncology Market Opportunities
  • 3.4. RWE Oncology Market Future Trends

4. RWE Oncology Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. RWE Oncology Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. RWE Oncology Market Landscape

  • 6.1. RWE Oncology Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. RWE Oncology Market - By Component

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Component, 2024 & 2032 (%)
    • 7.1.2. Datasets
      • 7.1.2.1. EMR/HER
      • 7.1.2.2. Claims
      • 7.1.2.3. Pharmacy
      • 7.1.2.4. Cancer Registries
    • 7.1.3. Integrated Datasets
    • 7.1.4. Consulting Services

8. RWE Oncology Market - By Data Source Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Data Source Type, 2024 & 2032 (%)
    • 8.1.2. Clinical Data
    • 8.1.3. Claims Data
    • 8.1.4. Oncology Registries
    • 8.1.5. Pharmacy Data

9. RWE Oncology Market - By Therapeutic Area

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Therapeutic Area, 2024 & 2032 (%)
    • 9.1.2. Breast Cancer
    • 9.1.3. Lung Cancer
    • 9.1.4. Prostate Cancer
    • 9.1.5. Hematologic Malignancies
    • 9.1.6. Others

10. RWE Oncology Market - By Application

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
    • 10.1.2. Drug Development & Approvals
    • 10.1.3. Market Access & Reimbursement
    • 10.1.4. Post-Market Surveillance
    • 10.1.5. Medical Device Approvals
    • 10.1.6. Others

11. RWE Oncology Market - By End User

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
    • 11.1.2. Pharmaceutical, Biotechnology & Medical Device Companies
    • 11.1.3. Healthcare Providers
    • 11.1.4. Healthcare Payers
    • 11.1.5. Others

12. RWE Oncology Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. RWE Oncology Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. RWE Oncology Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.10. UK
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. UK Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.3.10.4. UK Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.3.10.5. UK Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.10.6. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.10.7. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.11. France
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. France Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.3.11.4. France Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.3.11.5. France Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.11.6. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.11.7. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.12. Italy
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. Italy Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.3.12.4. Italy Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.3.12.5. Italy Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.12.6. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.12.7. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.13. Spain
      • 12.3.13.1. Overview
      • 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.3. Spain Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Spain Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Spain Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.13.7. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.14. The Netherlands
      • 12.3.14.1. Overview
      • 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.3. The Netherlands Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.3.14.4. The Netherlands Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.3.14.5. The Netherlands Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.14.6. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.14.7. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Overview
      • 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.15.7. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.16. Russia
      • 12.3.16.1. Overview
      • 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.3. Russia Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Russia Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Russia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.16.7. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.17. Poland
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Poland Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Poland Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Poland Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.18. Rest of Europe
      • 12.3.18.1. Overview
      • 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.18.3. Rest of the Europe Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.3.18.4. Rest of the Europe Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.3.18.5. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.18.6. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.18.7. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. RWE Oncology Key Manufacturers in Asia Pacific
    • 12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. APAC Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
    • 12.4.5. APAC Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
    • 12.4.6. APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.4.7. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.8. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.9. China
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. China Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.4.9.4. China Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.4.9.5. China Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.9.6. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.9.7. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.10. India
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. India Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.4.10.4. India Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.4.10.5. India Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.10.6. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.10.7. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.14. Indonesia
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Indonesia Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Indonesia Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Indonesia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.15. Thailand
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Thailand Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Thailand Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Thailand Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.5. Latin America (LATAM)
    • 12.5.1. Overview
    • 12.5.2. RWE Oncology Key Manufacturers in Latin America
    • 12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. LATAM Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
    • 12.5.5. LATAM Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
    • 12.5.6. LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.5.7. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.8. LATAM Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. RWE Oncology Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- RWE Oncology Industry

  • 13.1. Competitive Benchmarking
    • 13.1.1. Competitive Dashboard
    • 13.1.2. Competitive Positioning
  • 13.2. Company Profiles
    • 13.2.1. IQVIA
    • 13.2.2. ICON plc
    • 13.2.3. Syneos Health
    • 13.2.4. Parexel International
    • 13.2.5. Covance (Labcorp)
    • 13.2.6. PPD, Inc.
    • 13.2.7. PRA Health Sciences (now part of ICON)
    • 13.2.8. Charles River Laboratories
    • 13.2.9. Medidata Solutions (Dassault Systemes)
    • 13.2.10. Clarivate
    • 13.2.11. Flatiron Health (owned by Roche)
    • 13.2.12. Cerner Corporation (now part of Oracle)
    • 13.2.13. Cota Healthcare
    • 13.2.14. Evidera (PAREXEL)
    • 13.2.15. RealEndeavors
    • 13.2.16. Truven Health Analytics (IBM Watson Health)
    • 13.2.17. Informa Pharma Intelligence
    • 13.2.18. McKesson Corporation
    • 13.2.19. Symphony Health (ICON)
    • 13.2.20. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us